FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W43569726> ?p ?o ?g. }

• W43569726 endingPage "40" @default.
• W43569726 startingPage "233" @default.
• W43569726 abstract "Neuroblastoma, a malignant tumor of infancy and childhood, has some very interesting peculiars: good prognosis, even with disseminated disease, propensity to occasionally undergo spontaneous regression, its ability to undergo spontaneous or induced differentiation to a benign ganglioneuroma. Neuroblastoma may originate anywhere along the sympathetic nervous system chain. The most common site of primary tumor is, however, within the abdomen either in the adrenal gland or in a paraspinal ganglions. A great deal of progress has been made in advancing the knowledge of human neuroblastoma at the cellular and molecular viewpoint. The genetic predisposition to develop the tumor is clarified, a specific oncogene amplified (N-myc) in neuroblastoma cells shows precise prognostic significance and the deletion of chromosome 1's short arm has been defined. Work-up in neuroblastoma's diagnosis include the urine assay for catecholamine metabolites (VMA, HAVA, VLA) and serum assay for the specific markers as neuron-specific enolase (NSE), ferritin, GD2 ganglioside. Imaging include CT-scan, MIGB body-scan and the newest monoclonal antibodies scan. Abdominal tumors are shown in about 75% of children > 12 months old. In 2/3 of cases, tumor is widely disseminated at the time of diagnosis. In the period 1979-94 the Italian Group for Neuroblastoma (GCN-AIEOP) collected 1083 cases of tumors and 5-yrs survival was 45% +/- 2.4 for the patients studied in the period 1979-84, which is increased to 58% +/- 3 for the group of patients 1990-94 (p < 0.001). The overall survival was 53 +/- 1.7. About 5-yrs survival at different stages, AIEOP shows that it is increased from 88% +/- 3.3 (1979-84 group) to 91% +/- 2.8 (1985-92) in the stage I and II (280 cases). In the stage IV survival value improved from 79% +/- 7.1 to 84% +/- 7 (132 cases). No statistical improvement can be observed, anyway. Better improvements can be pointed out in stage III (221 cases, survival from 48% +/- 5.2 (79-84 group) to 69% +/- 4.8 (85-92) and stage IV (483 cases, survival from 16% +/- 2.6 to 28% +/- 3.4) (p < 0.001). Finally we can summarize about neuroblastoma: 1) better prognosis in the first year of life; 2) ability to spontaneous regression, first of all, in stage IVs; 3) partial and provisional response to therapy in advanced stages; 4) no recovery increasing despite advancing in surgery and chemotherapy." @default.
• W43569726 created "2016-06-24" @default.
• W43569726 creator A5002829562 @default.
• W43569726 creator A5064465226 @default.
• W43569726 creator A5077497327 @default.
• W43569726 date "1997-09-01" @default.
• W43569726 modified "2023-09-23" @default.
• W43569726 title "[Recent advances on retroperitoneal neuroblastoma]." @default.
• W43569726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9417295" @default.
• W43569726 hasPublicationYear "1997" @default.
• W43569726 type Work @default.
• W43569726 sameAs 43569726 @default.
• W43569726 citedByCount "0" @default.
• W43569726 crossrefType "journal-article" @default.
• W43569726 hasAuthorship W43569726A5002829562 @default.
• W43569726 hasAuthorship W43569726A5064465226 @default.
• W43569726 hasAuthorship W43569726A5077497327 @default.
• W43569726 hasConcept C142724271 @default.
• W43569726 hasConcept C188618488 @default.
• W43569726 hasConcept C204232928 @default.
• W43569726 hasConcept C2776715637 @default.
• W43569726 hasConcept C2779102060 @default.
• W43569726 hasConcept C2780582931 @default.
• W43569726 hasConcept C2780694816 @default.
• W43569726 hasConcept C54355233 @default.
• W43569726 hasConcept C71924100 @default.
• W43569726 hasConcept C81885089 @default.
• W43569726 hasConcept C86803240 @default.
• W43569726 hasConceptScore W43569726C142724271 @default.
• W43569726 hasConceptScore W43569726C188618488 @default.
• W43569726 hasConceptScore W43569726C204232928 @default.
• W43569726 hasConceptScore W43569726C2776715637 @default.
• W43569726 hasConceptScore W43569726C2779102060 @default.
• W43569726 hasConceptScore W43569726C2780582931 @default.
• W43569726 hasConceptScore W43569726C2780694816 @default.
• W43569726 hasConceptScore W43569726C54355233 @default.
• W43569726 hasConceptScore W43569726C71924100 @default.
• W43569726 hasConceptScore W43569726C81885089 @default.
• W43569726 hasConceptScore W43569726C86803240 @default.
• W43569726 hasIssue "4" @default.
• W43569726 hasLocation W435697261 @default.
• W43569726 hasOpenAccess W43569726 @default.
• W43569726 hasPrimaryLocation W435697261 @default.
• W43569726 hasRelatedWork W1591100935 @default.
• W43569726 hasRelatedWork W1965994449 @default.
• W43569726 hasRelatedWork W1996908622 @default.
• W43569726 hasRelatedWork W2026028175 @default.
• W43569726 hasRelatedWork W2092109441 @default.
• W43569726 hasRelatedWork W2154081118 @default.
• W43569726 hasRelatedWork W2316140216 @default.
• W43569726 hasRelatedWork W266361811 @default.
• W43569726 hasRelatedWork W43569726 @default.
• W43569726 hasRelatedWork W62657888 @default.
• W43569726 hasVolume "69" @default.
• W43569726 isParatext "false" @default.
• W43569726 isRetracted "false" @default.
• W43569726 magId "43569726" @default.
• W43569726 workType "article" @default.